千金药业：下属公司盐酸鲁拉西酮片获药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479) announced that its subsidiary, Qianjin Xiangjiang Pharmaceutical, received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating schizophrenia [1] Group 1 - The approval of Lurasidone Hydrochloride Tablets marks a key milestone for the company in expanding its therapeutic offerings [1] - This product is specifically indicated for the treatment of schizophrenia, which addresses a critical area in mental health [1]